ArticleBlood cancer journal2025

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.

Carlos Jimenez-Vicente et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.